<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00892762</url>
  </required_header>
  <id_info>
    <org_study_id>C-09-001</org_study_id>
    <nct_id>NCT00892762</nct_id>
  </id_info>
  <brief_title>Travoprost APS Versus Xalatan® in Patient Reported Outcomes and Ocular Surface Health</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand differences in visual function-related
      patient-reported outcomes between a non-BAK medication (Travoprost APS) and a BAK-preserved
      medication (XALATAN®) in patients with open-angle glaucoma or ocular hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean NEI VFQ-25 composite score at the end of the treatment period (Day 90)</measure>
    <time_frame>Day 90</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">434</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Travoprost APS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Travoprost APS 40 micrograms/ml eye drop solution, 1 drop in the study eye(s), once daily each evening, for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XALATAN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Latanoprost 50 micrograms/ml eye drop solution, 1 drop in the study eye(s), once daily each evening, for 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost APS 40 micrograms/ml eye drop solution</intervention_name>
    <description>non-BAK (benzalkonium chloride) medication</description>
    <arm_group_label>Travoprost APS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost 50 micrograms/ml eye drop solution</intervention_name>
    <description>BAK-preserved medication</description>
    <arm_group_label>XALATAN</arm_group_label>
    <other_name>XALATAN®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have a clinical diagnosis of open-angle glaucoma (with or without
             pseudoexfoliation or pigment dispersion component), or ocular hypertension in at least
             1 eye.

          -  Must be willing and able to discontinue use of any topical ocular medication other
             than the study medication for the duration of the study.

          -  Must have had Intraocular Pressure (IOP) controlled with mono-therapy using XALATAN®
             for at least 1 continuous month prior to Visit 1.

          -  Women of childbearing potential must meet all of the following conditions at Visit 1:

               -  They are not breast-feeding.

               -  They have a negative urine pregnancy test at Visit 1.

               -  They agree to undertake a urine pregnancy test upon entering and exiting the
                  study.

               -  They are not planning to become pregnant during the course of the study.

               -  They are currently using, and agree to use adequate birth control methods for the
                  duration of the study.

          -  Other protocol-specified inclusion criteria may apply.

        Exclusion Criteria:

          -  Any abnormality preventing reliable applanation tonometry in the study eye(s).

          -  Presence of any ocular pathology in either eye seen during the slit lamp or fundus
             exams, that in the opinion of the Investigator may preclude the safe administration of
             test article or safe participation in this study.

          -  Dry eye or keratoconjunctivitis sicca (KCS) which has been, or is currently being,
             treated with the use of punctal plugs, punctal cautery, Restasis®, or topical ocular
             corticosteroids.

          -  Patients who have undergone keratorefractive ocular laser procedures, corneal surgery
             or surgery to the corneal surface, including but not limited to LASIK and PRK, within
             6 months prior to Visit 1.

          -  Patients who have undergone intraocular or extra-ocular surgery, in either eye, within
             6 months prior to Visit 1.

          -  Any history of ocular infections or inflammatory ocular conditions within the past 3
             months in either eye.

          -  Use of any systemic medications on a chronic basis that have not been on a stable
             dosing regimen for at least 30 days prior to Visit 1.

          -  Use of ocular medications other than XALATAN® within 7 days of Visit 1.

          -  Use of corticosteroids within 30 days of Visit 1.

          -  Use of contact lenses within 30 days of Visit 1. Concomitant use of contact lenses is
             also excluded for the duration of the study.

          -  History of intolerance or hypersensitivity to any component of the test articles.

          -  Participation in an investigational drug or device study within 30 days of entering
             this study.

          -  History or evidence of corneal transplant or transplant variant procedures.

          -  Other protocol-specified exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theresa Landry, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2009</study_first_submitted>
  <study_first_submitted_qc>May 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2009</study_first_posted>
  <disposition_first_submitted>July 11, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>July 11, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 15, 2014</disposition_first_posted>
  <last_update_submitted>July 11, 2014</last_update_submitted>
  <last_update_submitted_qc>July 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Open Angle Glaucoma</keyword>
  <keyword>Ocular hypertension</keyword>
  <keyword>OAG</keyword>
  <keyword>OH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
    <mesh_term>Travoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

